Renal Cancer - Results from #2260

ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma. January 25, 2021

Radical metastasectomy followed by sorafenib versus observation in patients with clear cell renal cell carcinoma: extended follow up of efficacy results from the randomized phase II RESORT trial. January 25, 2021

Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival. January 25, 2021

External validation of the albumin, C-reactive protein and lactate dehydrogenase model in patients with metastatic renal cell carcinoma receiving second-line axitinib therapy in a Japanese multi-center cohort. January 25, 2021

Dana-Farber Research Supports FDA Approval for Combination of Nivolumab and Cabozantinib in Advanced Kidney Cancer January 23, 2021

Cabozantinib Receives U.S. FDA Approval as a First-Line Treatment in Combination with Nivolumab for Advanced Renal Cell Carcinoma January 22, 2021

The prognostic impact of immune-related adverse events in metastatic renal cell carcinoma patients treated with nivolumab: a real-world multi-institutional retrospective study. January 22, 2021

Prognostic role of PHYH for overall survival (OS) in clear cell renal cell carcinoma (ccRCC). January 22, 2021

Circular RNA circSDHC serves as a sponge for miR-127-3p to promote the proliferation and metastasis of renal cell carcinoma via the CDKN3/E2F1 axis. January 22, 2021

Otoferlin is a prognostic biomarker in patients with clear cell renal cell carcinoma: A systematic expression analysis. January 21, 2021

Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. January 21, 2021

Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. January 21, 2021

CircPVT1 promotes progression in clear cell renal cell carcinoma by sponging miR-145-5p and regulating TBX15 expression. January 20, 2021

Deep learning based prediction of prognosis in nonmetastatic clear cell renal cell carcinoma. January 20, 2021

Prevalence of pathogenic germline variants in patients with metastatic renal cell carcinoma. January 19, 2021

Validation of CT radiomics for prediction of distant metastasis after surgical resection in patients with clear cell renal cell carcinoma: exploring the underlying signaling pathways. January 19, 2021

Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC). January 18, 2021

Available active surveillance follow-up protocols for small renal mass: a systematic review. January 18, 2021

Low-Dose Nivolumab in Renal Cell Carcinoma: A Real-World Experience. January 15, 2021

Update on First-Line Combination Treatment Approaches in Metastatic Clear-Cell Renal Cell Carcinoma. January 15, 2021

Page 114 of 458